Generate Biomedicines Inc (NASDAQ:GENB) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Generate Biomedicines Inc (NASDAQ:GENB) have earned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $25.40.

A number of analysts have weighed in on the company. Guggenheim started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price target on the stock. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. The Goldman Sachs Group assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 target price for the company. Cantor Fitzgerald started coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating on the stock. Finally, HC Wainwright raised their price objective on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, May 8th.

Generate Biomedicines Trading Down 2.2%

Shares of GENB stock opened at $16.50 on Thursday. The stock has a market capitalization of $2.12 billion and a price-to-earnings ratio of -15.42. Generate Biomedicines has a 1-year low of $11.00 and a 1-year high of $18.18. The stock’s 50-day moving average is $14.02.

Generate Biomedicines (NASDAQ:GENB) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.